Fulgent Genetics, Inc.
As of Oct 22, 2026, Fulgent Genetics is in Stage 2, the uptrend phase, now in week 3 (since Oct 2, 2026). It closed at $19.99, 35.2% below its 52-week high and above its 200-day average, which is falling.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is FLGT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
FLGT among Diagnostics & Research32nd of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …32 | FLGT | Stage 2 · wk 3 | 42 | −6.0% |
Fulgent Genetics: quick answers
What stage is Fulgent Genetics in?
As of Oct 22, 2026, Fulgent Genetics (FLGT) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 2, 2026 and is in week 3. What the four stages mean
Is Fulgent Genetics in an uptrend?
Yes. Fulgent Genetics is in a Stage 2 uptrend. It trades 2.0% above its 200-day average, which is falling.
How far is Fulgent Genetics from its 52-week high?
Fulgent Genetics closed at $19.99 on Oct 22, 2026, 35.2% below its 52-week high of $30.85. Its 52-week low is $13.79.
How has Fulgent Genetics performed over the past year?
As of Oct 22, 2026, Fulgent Genetics is down 16.6% over the past year and down 21.9% so far in 2026.
Which sector and industry is Fulgent Genetics in?
Fulgent Genetics is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.